Coronavirus Information for the UC San Diego Community

Our leaders are working closely with federal and state officials to ensure your ongoing safety at the university. Stay up to date with the latest developments. Learn more.

The future of microbiome-based therapeutics in clinical applications

TitleThe future of microbiome-based therapeutics in clinical applications
Publication TypeJournal Article
Year of Publication2020
AuthorsSharma A., Das P., Buschmann M., Gilbert J.A
Volume107
Pagination123-128
Date Published2020/01
Type of ArticleReview
ISBN Number0009-9236
Accession NumberWOS:000512979000031
Keywordsactive ulcerative-colitis; bacteria; cancer; donor; efficacy; Gut Microbiome; intestinal microbiota; irinotecan cpt-11; metabolism; Pharmacology & Pharmacy; transplantation
Abstract

The microbiome, a collection of microorganisms, their genomes, and the surrounding environmental conditions, is akin to a human organ, and knowledge is emerging on its role in human health and diseases. The influence of the microbiome in drug response has only been investigated in detail for the last 10 years. The human microbiome is a complex and highly dynamic system, which varies dramatically between individuals, yet there exists a common core microbiome that is heritable and can be transmitted to progeny. Here, we review the role of the human microbiome, which is now widely accepted as a major factor that drives the interpersonal variation in therapeutic response. We describe examples in which the microbiome modifies drug action. Despite its complexity, the microbiome can be readily altered, with the potential to increase the benefits and reduce the toxicity and side effects associated with pharmaceutical drugs. The potential of new microbiome-based strategies, such as fecal microbiota transplant, probiotics, and phage therapy, as promising medical therapeutics are outlined. We also suggest a combination reductionist and system-level approaches that could be applied to further investigate the role of microbiota in drug metabolism modulation of drug response. Finally, we emphasize the importance of combining microbiome and pharmacology studies as a novel means to treat disease and reduce side effects.

DOI10.1002/cpt.1677
Student Publication: 
No
Research Topics: